ADAPTIMMUNE THERAPEUTICS PLC Debt Securities, Available-for-sale, Unrealized Loss Position
ADAPTIMMUNE THERAPEUTICS PLC (ADAPY) had Debt Securities, Available-for-sale, Unrealized Loss Position of $1.48 million as of 2024-09-30, per its 10-Q filed 2024-11-13.
Financial Statements › Notes › Debt and Equity Securities
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition · last filed 2024-11-13
- 2024-09-30: Debt Securities, Available-for-sale, Unrealized Loss Position $1.48M.
- 2024-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position $1.99M.
- 2023-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position $1.60M.
- 2023-09-30: Debt Securities, Available-for-sale, Unrealized Loss Position $26.69M.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position | Debt Securities, Available-for-sale, Unrealized Loss Position as first filed |
|---|---|---|
| 2024-09-30 | $1.48M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $1.99M 10-Q · filed 2024-08-12 | |
| 2023-12-31 | $1.60M 10-Q · filed 2024-11-13 | |
| 2023-09-30 | $26.69M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $61.48M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $45.69M 10-Q · filed 2023-05-12 | |
| 2022-12-31 | $90.62M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $156.63M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $188.96M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $176.48M 10-K · filed 2023-03-06 | |
| 2020-12-31 | $157.99M 10-K · filed 2022-03-14 | |
| 2020-09-30 | $135.00M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $168.20M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $90.90M 10-Q · filed 2020-05-14 | |
| 2019-12-31 | $2.00M 10-Q · filed 2020-11-05 | |
| 2019-09-30 | $7.20M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $9.60M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $49.57M 10-Q · filed 2019-05-06 | |
| 2018-12-31 | $117.20M 10-Q · filed 2019-11-06 | $117.18M 10-Q · filed 2019-05-06 |
| 2018-09-30 | $79.48M 10-Q · filed 2018-11-06 | |
| 2017-12-31 | $125.83M 10-Q · filed 2018-11-06 |